North America Human Insulin Drugs Market Share

Statistics for the 2023 & 2024 North America Human Insulin Drugs market share, created by Mordor Intelligence™ Industry Reports. North America Human Insulin Drugs share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Share of North America Human Insulin Drugs Industry

The North American human insulin market is highly fragmented, with three major manufacturers having a large market share. In the United States, there are no other players except Novo Nordisk, Sanofi, and Eli Lilly. In the remaining countries, the manufacturers confine themselves to other local or region-specific manufacturers. Mergers and acquisitions that happened between the players in the recent past helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim have an alliance to develop and commercialize Basaglar (insulin glargine).

North America Insulin Market Leaders

  1. Sanofi S.A.

  2. Novo Nordisk A/S

  3. Eli Lilly and Company

  4. Pfizer Inc

  5. Biocon Limited

*Disclaimer: Major Players sorted in no particular order

North America Human Insulin Drugs Market Concentration

North America Insulin Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)